Edition:
India

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

7.88USD
17 Nov 2017
Change (% chg)

$-0.14 (-1.75%)
Prev Close
$8.02
Open
$8.00
Day's High
$8.01
Day's Low
$7.60
Volume
34,582
Avg. Vol
68,997
52-wk High
$9.22
52-wk Low
$3.76

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

02 Nov 2017

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

11 Sep 2017

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

07 Sep 2017

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

07 Sep 2017

BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting

* Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting

05 Jun 2017

Earnings vs. Estimates